Who is this trial for: This trial is for patients with one of three forms of non-small cell lung cancer (NSCLC) – ALK, ROS1, or RET - who are progressing on their current TKI under certain conditions, and are willing to try an experimental drug combination in order to extend the life of their current TKI.  Amivantamab is a bi-specific antibody targeting the cell survival pathways MET and EGFR.  The trial may be most appropriate for patients who are progressing without a targetable mutation or clearly identified driver of their cancer growth.

 

Read More